123 studies found for:    Open Studies | niaid
Show Display Options
Rank Status Study
21 Not yet recruiting Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: Placebo for VRC01
22 Recruiting Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation
Conditions: Liver Transplant;   Liver Transplantation
Intervention: Procedure: Immunosuppression withdrawal
23 Recruiting Subcutaneous Immunotherapy for Mouse in Adults
Conditions: Asthma;   Perennial Allergic Rhinitis,
Intervention: Biological: Mouse Allergenic Extract
24 Not yet recruiting Integrase and Maraviroc Intensification for Neurocognitive Dysfunction (InMIND)
Condition: HIV Infections
Interventions: Drug: Placebo for maraviroc (MVC);   Drug: Placebo for dolutegravir (DTG);   Drug: Dolutegravir (DTG);   Drug: Maraviroc (MVC)
25 Recruiting Registry for Asthma Characterization and Recruitment 2
Condition: Asthma
Intervention:
26 Recruiting Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy
Condition: Asthma
Intervention:
27 Recruiting Effects of Inhibiting Early Inflammation in Kidney Transplant Patients
Condition: Kidney Transplant
Interventions: Biological: Infliximab;   Drug: Methylprednisolone;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Biological: Thymoglobulin;   Drug: Acetaminophen;   Drug: Loratadine;   Biological: Placebo for Infliximab;   Drug: Prednisone;   Drug: Diphenhydramine
28 Not yet recruiting Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults
Condition: HIV Infections
Intervention: Drug: Ruxolitinib
29 Recruiting Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction
Conditions: Liver Transplant Recipient;   Living Donor (of the Respective Liver Transplant Recipient)
Interventions: Biological: darTregs;   Drug: Acetaminophen;   Drug: Diphenhydramine;   Drug: Immunosuppression (IS) Withdrawal;   Procedure: Study Mandated Procedures
30 Recruiting Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2
Condition: Dengue
Interventions: Biological: Recombinant live attenuated trivalent dengue vaccine;   Biological: Placebo;   Biological: rDEN2Δ30-7169 vaccine
31 Recruiting Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: PENNVAX®-GP HIV-1 DNA vaccine;   Biological: Interleukin-12 (IL-12) DNA adjuvant;   Biological: Placebo
32 Recruiting Autologous Polyclonal Tregs for Lupus
Conditions: Lupus Erythematosus, Cutaneous;   Lupus Erythematosus, Discoid;   Lupus Erythematosus, Systemic
Intervention: Biological: Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells
33 Recruiting Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults
Condition: Dengue
Interventions: Biological: rDEN1Δ30;   Biological: Placebo;   Biological: rDEN2Δ30-7169
34 Recruiting Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Conditions: HIV Infections;   Cardiovascular Diseases
Interventions: Drug: Pitavastatin;   Drug: Placebo
35 Recruiting Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and Children in Thailand
Condition: Dengue
Interventions: Biological: TV003;   Biological: Placebo for TV003
36 Recruiting Fel d 1 Peptide Immunotherapy Clinical Trial
Conditions: Cat Allergy;   Cat Hypersensitivity
Interventions: Drug: Cat-PAD;   Drug: Placebo
37 Recruiting Tocilizumab (TCZ) in New-onset Type 1 Diabetes
Conditions: Type 1 Diabetes Mellitus;   New-onset Type 1 Diabetes Mellitus;   T1DM;   T1D
Interventions: Drug: Tocilizumab (TCZ);   Drug: Placebo
38 Recruiting Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza
Conditions: Influenza A;   Influenza B
Interventions: Biological: Intravenous hyperimmune immunoglobulin (IVIG);   Biological: Placebo for IVIG
39 Recruiting B Cell Induction in Pediatric Lung Transplantation
Condition: Lung Transplant
Interventions: Biological: Rituximab (Rituxan®);   Biological: Placebo
40 Recruiting Rituximab and Belimumab for Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Biological: Rituximab;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Methylprednisolone;   Drug: Diphenhydramine;   Drug: Acetaminophen;   Biological: Belimumab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years